<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00821483</url>
  </required_header>
  <id_info>
    <org_study_id>FRESH</org_study_id>
    <nct_id>NCT00821483</nct_id>
  </id_info>
  <brief_title>A Double Blind Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Frovatriptan in the Acute Treatment of Migraine</brief_title>
  <official_title>Phase 3 Study to Assess the Efficacy and Safety of Frovatriptan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SK Chemicals Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SK Chemicals Co.,Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is:

        1. To compare the efficacy of a single dose of Frovatriptan 2.5 mg with that of placebo in
           acute treatment of up to one migraine attract

        2. To assess recurrence rate between two group

        3. To assess the safety and tolerability
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>A comparison between Frovatriptan and placebo for the proportion of patients who have complete(grade 0) or almost complete(grade 1) relief of headache at 2 hours after taking Frovatriptan</measure>
    <time_frame>at 2 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">298</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>1: placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2 Frovatriptan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Frovatriptan</intervention_name>
    <description>2.5mg, qd</description>
    <arm_group_label>1: placebo</arm_group_label>
    <arm_group_label>2 Frovatriptan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adults aged 18 to 65 years

          2. The patients must have a history of migraine according to the criteria of the Headache
             Classification Committee of the International Headache Society(IHS), over the previous
             1 year. The patient must have experienced one to eight moderate or severe migraine
             attacks(with or without aura) each month over at least the previous two months

          3. Onset of migraine disease must have occurred before the patients was 50 years of age

          4. Able and willing to sign informed consent, and able and willing to comply with study
             procedures, including the completion of diary cards.

        Exclusion Criteria:

          1. Pregnant or lactating females, or women intend to become pregnant or breast feed
             during the study period, or women of childbearing potential not using adequate
             contraception. Females of reproductive potential must have a negative pregnancy test
             at screening

          2. Clinically significant renal dysfunction(creatinine≥2.0mg/dl) or hepatic
             dysfunction(ALT,AST≥2 ULN)

          3. Patients with clinically significant abnormal ECGs or with resting diastolic blood
             pressure above 95mmHg

          4. Patients with clinically significant cardiovascular or cerebrovascular disease

          5. Patients with a history of clinically relevant allergy, including allergy to triptan

          6. Previous treatment with Frovatriptan at any time or treatment with an investigational
             drug within 30 days before screening visit

          7. Patients with a diagnosis of vertebrobasilar or hemiplegic(prolonged atypical aura)
             migraine(IHS criteria)

          8. Potentially unco-operative patients, those unable to provide informed consent, and
             those unable to complete the diary

          9. patients who habitually abuse headache medication including ergotamine-containing
             compounds, and patients with a history of alcohol and/or medicine abuse, in the
             Investigator's opinion

         10. Patients who are not able to tell that they are having a migraine headache

         11. Patients who have 15 or more headache days per month, on average, or those taking
             symptomatic medication for headaches on more than two days per week, on average

         12. Treatment with a monoamine-oxidase inhibitor(MAOI) within two weeks of the screening
             visit

         13. Patients who are taking prophylactic migraine medication, unless dose has been
             stabilized for 30 days and it expected to continue for the duration of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sun U Kwon, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neurology, Asan Medical Center, University of Ulsan</affiliation>
  </overall_official>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2009</study_first_submitted>
  <study_first_submitted_qc>January 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2009</study_first_posted>
  <last_update_submitted>April 16, 2013</last_update_submitted>
  <last_update_submitted_qc>April 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Frovatriptan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

